Immunicon — Investor Presentation (February 2005)
32 slides from Immunicon's investor presentation, Feb 17, 2005
Slide 1: Cellular Information for Better Healthcare
© IMMUNICON Cellular Information for Better Healthcare Management Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements that reflect management's current views and opinions as to the status of the Company’s products, clinical trials, regulatory approval process, product development, research programs and other future events and operat
Slide 3: Section 1: Company Overview
SECTION 1 Company Overview
Slide 4: Company Overview
Company Overview Immunicon develops and is commercializing products for rare cell analysis with an initial focus in cancer: ¢ All FDA clearances for initial products received ¢ IVD commercialization in progress Strategic alliance with Johnson & Johnson in cancer High impact clinical diagnostic produ
Slide 5: Circulating Tumor Cells (CTCs) in Cancer Diagnostics
Circulating Tumor Cells (CTCs) in Cancer Diagnostics ABC World News Tonight 8/18/04 © IMMUNICON
Slide 6: The Problem
The Problem Risk Assessment and Early Detection Select and Monitor Therapy in Metastatic Disease Monitor Effectiveness of Post-Surgical Therapy and Recurrence Diagnosis, Staging and Selection of Primary Therapy @ IMMUNICON
Slide 7: Section: Technology and Products
SECTION 2 Technology and Products
Slide 8: "Real-Time Biopsy" Using a Blood Sample
“Real-Time Biopsy” Using a Blood Sample Circulating Tumor Cells (CTCs) and Associated Markers: Assess Prognosis Count Imm Direct Therapy Monitor Disease Phenotype Diagnose & Genotype — Specify Therapy Determine Risk Assessment for Presence Lad Cancer Most tumors are of epithelial cell origin: Isolat
Slide 9: CellTracks Technology
CellTracks® Technology Nucleic Acid/Protein Analyses La 4celitracks Cell Search Kits & Markers 4cellspotter 4celitracks 4celltracks ie SS © IMMUNICON
Slide 10: A New Paradigm for Cancer Disease Management
A New Paradigm for Cancer Disease Management Current standard: Potential future standard: Radiologist measures changes in Number andlor makeup of CTCs better lesions on a CT scan to assess reflects efficacy of treatment tumor burden increase/decrease Subjective and semi-quantitative | Objective and
Slide 11: NEJM 8/19/04: CTCs Predict Survival
NEJM 8/19/04: CTCs Predict Survival Before initiation of therapy 100% >18 months 10.1 months ; 25 CTCs (N=87) %Probability of Survival 8 ze rl 10% H N=177 0%-| : Logrank < 0.0001 05 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 Time from start of therapy (Weeks) © IMMUNICON
Slide 12: NEJM 8/19/04: CTCs Predict Response to Therapy
NEJM 8/19/04: CTCs Predict Response to Therapy %Probability of Survival 10% ~4 weeks after initiation of therapy <5 CTCs (N=114) >18 Months 7.0 months | N=163 Logrank < 0.0001 tt a es 0° 5 40 45 20 25 30°35 40 45 50 85 60 65°70 75 80 Time from 1st Follow-Up (Weeks) © IMMUNICON
Slide 13: NEJM 8/19/04: Proven Clinical Utility
NEJM 8/19/04: Proven Clinical Utility ¢ Current measures to determine if therapy is effective are inadequate, especially early on in the treatment regimen Circulating tumor cells (CTCs) may provide early evidence of therapeutic futility #CTCs are an independent prognostic indicators of favorable & u
Slide 14: New FDA Classification
New FDA Classification Classification under “de novo” process: Simplifies and shortens regulatory timelines @ = 510(k) versus PMA process @ Creates a significant barrier to entry FDA cleared labeling: @ The presence of CTC[s] in the peripheral blood, as detected by the CellSearch™ Circulating Tumor
Slide 15: "Real-Time Biopsy" from a Blood Sample
“Real-Time Biopsy” from a Blood Sample Enables selection of targeted therapies Taxol Herceptin 225 cod 2 | * |e { “| O° 475. E 150 x Gs BB tera +++ Her ++ = 100 3 7 Do xer2+ Bf Her2- © 50 5 2 0 | = = 0123 45 67 8 9 101112131415 16 17 18 19 20 Time (weeks) > IntJOncol 21: 1111-1118, 2002 1“ © IMMUNIC
Slide 16: Summary of additional key clinical/scientific findings
6 Summary of additional key clinical/scientific findings Breast Cancer - “Bone only" disease data encouraging ~ CTCs predict outcome during the course of therapy — CTCs a stronger predictor of outcome versus imaging Colorectal Cancer — Planned interim analysis encouraging — ~400 patient labeling stu
Slide 17: Completed Modular System
6 Completed Modular System Low incremental cost to add new applications Sample Collection and Preservation Sample Sample Sample Preparation Mf Presentation Analysis Reports Processed Samples for Off-Line Analyses © IMMUNICON
Slide 18: Many Product Opportunities
Many Product Opportunities ¢ Potential follow-on CTC applications — Other carcinomas — colorectal, prostate, other carcinomas... — Other settings — diagnosis, recurrence, risk assessment, ... — Nucleic acid and protein markers ¢ Endothelial cells — Cancer — angiogenesis — Cardiovascular, autoimmune.
Slide 19: Circulating Endothelial Cells (CECs)
Circulating Endothelial Cells (CECs) CECs are implicated in cancer, cardiovascular disease, and many other diseases and conditions CECs detected by Immunicon system © IMMUNICON
Slide 20: Section: Commercialization
SECTION 3 Commercialization
Slide 21: Significant Market Opportunity
Significant Market Opportunity Overall U.S. Market Cancer is the second leading killer — Prevalence: 8.9 million survivors — Incidence: 1.3 million new diagnoses p.a. — Mortality: 500,000 deaths p.a. #~86% of all cancers are carcinomas (solid tumors) —CellSearch™ System is “pan-carcinoma” Cancer Fac
Slide 22: Significant Market Opportunity
Significant Market Opportunity Cancer Metastatic Pool Breast 78,809 Colorectal 71,136 Prostate 60,449 Lung & bronchus 147,693 Urinary System 29,226 Corpus uteri 8,720 Other Carcinoma 105,525 Sub-total 501,558 Melanoma 13,298 TOTAL 514,855 Cancer Facts and Figures 2003, American Cancer Society a © IM
Slide 23: Strategic Alliance in Cancer with Johnson & Johnson
Strategic Alliance in Cancer with Johnson & Johnson Key elements: ¢ Immunicon develops and manufactures J8J finishes, sells and services @ Revenue shared (~30% to IMMC on reagents) @ Access to J8J technology, expertise and distribution @ Large equity investment by J&J Development Corp. © IMMUNICON
Slide 24: Selling the Benefits — Product Positioning
Selling the Benefits — Product Positioning Blood test ¢ Predictive = real impact in oncology @ “Real-time biopsy" = real-time medicine ¢@ Minimally invasive Convenient and cost-effective Fully integrated system Automation and standardization © IMMUNICON
Slide 25: Sales and Marketing Strategy
2 Sales and Marketing Strategy VEC IDExX< Oncologists @ IMMUNICON
Slide 26: Section: Financial Overview and Milestones
SECTION 4 Financial Overview and Milestones
Slide 27: Attractive Business Model
Attractive Business Model Everybody wins ¢ List price for instrument system = $120,000 + List price to lab for CTC test = $175.00 @ Fast payback for the hospital/reference lab @ High revenue/margins for J8J and Immunicon @ Cost effective for the patient/healthcare system Key Drivers for Reimbursemen
Slide 28: Financial Summary (2004)
Financial Summary (2004) Product sales of $1.1 million (mostly Q4) #18 systems shipped #10 to customers #8 to affiliates of J&J @Reference labs, hospitals and a pharma company USA, Europe and Japan ¢Total sales of $1.6 million (including milestones) $53.6 million cash/equivalents (12/31/04) $17 mill
Slide 29: Milestones Achieved
Milestones Achieved ¢ Initial Public Offering Q2/04 @ Publication in New England Journal of Medicine —_Q3/04 @ US. in vitro diagnostic (IVD) launch Q3/04 @ Announced deal with Quest Diagnostics Q3/04 @ Shipped units to Europe and Japan (RUO) Q28&Q3/04 @ Positive data in “bone only” breast cancer Q4/
Slide 30: Near-term Milestones
Near-term Milestones ¢ 510(k) clearance for CellTracks Analyzer II Q1/05 @ Launch CellTracks Analyzer II Q2/05 @ Publication in JCO on CTCs in 15 line Rx March 05 ¢ Abstract presentations at AACR April 05 ¢ Oral/poster presentations at ASCO May 05 ¢ Circulating Endothelial Cells (CECs) — Clinical re
Slide 31: Investment Highlights
Investment Highlights « Address unmet medical needs in large markets, starting with cancer @ Strategic partnership in cancer with Johnson & Johnson ~ 2004 revenue ~$1.1 million # Commercialization process well underway — Compelling clinical data ~ FDA clearances received/passed inspection - ISO 1348
Slide 32: Searchable text section of graphics shown above
Searchable text section of graphics shown above [ LOG O] Cellular Information for Better Healthcare Management Presentation For ward Looking Statements This presentation may contain forward-looking statements that reflect management’s current views and opinions as to the status of the Company’s prod